Safe and effective method of treating psoriasis with anti-IL-23 specific antibody

AU2026238030A1Pending Publication Date: 2026-10-15JANSSEN BIOTECH INC
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
AU2026238030
Authority / Receiving Office
AU · AU
Patent Type
Applications
Current Assignee / Owner
Priority Date
2019-10-15
Filing Date
2026-09-23
Publication Date
2026-10-15

Smart Images

  • Figure 00000192_0000
    Figure 00000192_0000
  • Figure 00000193_0000
    Figure 00000193_0000
  • Figure 00000193_0001
    Figure 00000193_0001
Patent Text Reader

Abstract

A method of treating psoriasis in a patient by administering an IL-23 specific antibody, e.g., guselkumab, in a clinically proven safe and clinically proven effective amount and the patient achieves PASI90, PASI100 or IGA 0 or 1 score as measured 16, 24, 32, 40 and 48 weeks after initial treatment and the patient achieves higher efficacy than a patient treated with the secukinumab antibody. 20 26 23 80 30 23 S ep 2 02 6 A B S T R A C T 2 0 2 6 2 3 8 0 3 0 2 3 S e p 2 0 2 6
Need to check novelty before this filing date? Find Prior Art